Inter- and intrasubject variability of the inflammatory response to segmental endotoxin challenge in healthy volunteers  by Holz, O. et al.
Inter- and intrasubject variability of the inﬂammatory response to
segmental endotoxin challenge in healthy volunteers
O. Holz a,b, L. Tan c, F. Schaumann a, M. Müller a, D. Scholl c, R. Hidi c, A. McLeod c,
N. Krug a,b, J.M. Hohlfeld a,b,*
a Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Clinical Airway Research, Hannover, Germany
b Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research, Hannover,
Germany
c Pﬁzer Ltd., Clinical Research, Sandwich, Kent, UK
A R T I C L E I N F O
Article history:
Received 20 July 2015
Received in revised form 2 October 2015
Accepted 30 October 2015
Available online 10 November 2015
Keywords:
Airway inﬂammation
Challenge model
Clinical drug development
Pharmacodynamic model
Reproducibility
Lipopolysaccharide (LPS)
A B S T R A C T
Segmental endotoxin challenge with lipopolysaccharide (LPS) can be used as a pharmacodynamic model
to safely induce a transient airway inﬂammation in the peripheral lung of healthy subjects and to test
the anti-inﬂammatory eﬃcacy of investigational new drugs. In contrast to whole lung LPS challenge only
a fraction of the dose is required that can be precisely administered to a speciﬁc lung region and a vehicle
challenged segment as an intra-subject control can be included. The aim of this study was to assess the
intra- and inter-individual variability of the response to segmental LPS challenge for the appropriate design
and power calculation of future clinical trials.
Two cohorts with 10 subjects each underwent two segmental LPS challenges within ﬁve weeks. The
inﬂammatory response was evaluated in bronchoalveolar lavage (BAL) ﬂuid at 6 (cohort 1) and 24 h
(cohort 2) both in the LPS and in a vehicle challenged segment, as well as in plasma for up to 26 h post
LPS challenge.
While the cytokine response was more pronounced at 6 h, the inﬂux of neutrophils and monocytes
dominated at 24 h; e.g. neutrophils increased from a median (inter-quartile range, IQR) of 0.14 (0.16)
and 0.09 (0.08)x104 cells/mL BAL ﬂuid at baseline to 10.2 (17.1) and 19.3 (15.9)x104 cells/mL 24 h after
the two separate challenges. The within-subject variability was higher than the between-subject vari-
ability for most of the markers. However, sample size estimations based on the variability of outcome
variables found lower or equal numbers with cross-over designs compared to parallel group designs for
cellular markers at 24 h and cytokine variables at 6 h.
The segmental LPS challenge model was safe. Future study designs have to balance between burden
to the study subjects (4 versus 2 bronchoscopies), variability (within-versus between-subject), and the
desired outcome variable (cells versus chemo/cytokine).
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Chronic obstructive pulmonary disease (COPD) is character-
ized by chronic inﬂammation of the airways with increased numbers
of neutrophils, monocytes/macrophages and CD8+ lymphocytes [1].
This inﬂammatory condition is associated with a variety of symp-
toms (cough, dyspnea, sputum production), progressive decline in
lung function, and recurrent exacerbations. While corticosteroid
treatment can ameliorate the course of an exacerbation, chronic in-
ﬂammation often does not respond suﬃciently to this treatment.
Therefore, there is an unmet need to develop novel anti-
inﬂammatory drugs in COPD.
Drug development of a novel anti-inﬂammatory agent demands
an early proof-of-mechanism in humans, preferably in the dis-
eased population. While airway inﬂammation in patients with COPD
is variable [2] and safety concerns may preclude administration of
investigational new drugs in patients with diminished organ
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function in early phases of clinical development, disease
models in healthy volunteers are warranted. This allows assessing
both safety and eﬃcacy to modulate airway inﬂammation
at acceptable risk. In this respect, different pharmacodynamic chal-
lenge models have been employed, such as the transient induction
of a neutrophilic airway inﬂammation in healthy subjects by
ozone challenge [3] or by challenge with lipopolysaccharide (LPS)
[4–6]. The feasibility of these approaches as a proof of mechanism
has been demonstrated for a novel CXCR2 antagonist using
ozone challenge [7] and for a PDE4 inhibitor using LPS challenge
[8,9].
LPS is a major component of the outer membrane of gram-
negative bacteria. Chronic exposure to LPS plays a role in the
development of dust-related occupational lung disease [10], and
LPS is a major component of cigarette smoke [11]. Puriﬁed LPS
has been safely administered to healthy human volunteers in
clinical models of lung inﬂammation either by inhalation
(whole lung deposition) or by segmental challenge [4–6,8,9]. LPS
causes an acute, transient systemic and pulmonary inﬂam-
matory response [4,6,12,13], the latter being characterised by
increased levels of airway neutrophils, CD8+ lymphocytes, mono-
cytes, macrophages and increased concentrations of TNF-alpha
(TNFA), interleukin-8 (IL8), and myeloperoxidase (MPO) in
sputum or bronchoalveolar lavage (BAL) [6], The pattern of
acute lung inﬂammation is similar to that observed in COPD
and therefore LPS challenge has been suggested [14] and em-
ployed as a potential clinical model to demonstrate pharma-
codynamics of novel anti-inﬂammatory agents for this disease
[8,9,15,16].
Inhaled challenges with LPS have been intensively used by various
groups to investigatemechanisms of airway inﬂammation in humans
[4,13,17]. Doses up to 100 μg have been safely applied to humans
with doses of about 20 μg LPS as a threshold dose for inducing
clinical symptoms and changes in pulmonary function [18]. In con-
trast, the threshold inhaled dose for inducing activation of
inﬂammatory cells (blood neutrophils) may be less than 0.5 μg
LPS [19]. As a pharmacodynamic challengemodel, LPS doses between
5 and 30 μg have been used. When using LPS as a challenge agent
in clinical trials, many countries require material which has been
produced according to good manufacturing practice (GMP). Due
to limited resources for GMP grade LPS, there is a need to develop
methods with low demand for LPS. In this respect, we have re-
cently shown that controlled inhalation of a low dose of 20.000
Endotoxin Units (EU, 2 μg LPS) can reproducibly induce an inﬂam-
matory response [20].
An alternative method that uses low doses of endotoxin is seg-
mental instillation of LPS by bronchoscopy which has ﬁrst been
described by O’Grady and colleagues [6]. Segmental LPS challenge
involves ﬂexible bronchoscopy and instillation of LPS into lung seg-
ments, with subsequent recovery of inﬂammatory cells and cytokines
by BAL. Although more invasive, it is generally well tolerated and
in studies to date without evidence of serious adverse effects or per-
sistent sequelae. Segmental LPS challenge has the advantage that
it allows the precise dosing of LPS to a speciﬁc lung segment and
at the same time the vehicle control administration to a different
lung segment, which is not possible in whole lung inhalation
challenges.
The aim of the current study was to further characterize the seg-
mental LPS challenge model by examining the intra- and inter-
subject variability of inﬂammatorymarkers as the basis for the design
of future clinical trials. Using a two cohort design, we assessed the
inﬂammatory response at either 6 h or 24 h post-LPS and investi-
gated the variability of the response by repeating the procedure
35 ± 7 days apart. We further aimed to assess the systemic inﬂam-
matory response to explore its reproducibility and relationship to
BAL ﬂuid markers.
2. Methods
2.1. Study design
In this two-period trial, subjects were allocated to one of two
cohorts assessing variability of inﬂammatory markers either at 6 h
(cohort 1) or 24 h (cohort 2) following segmental LPS challenge. Each
study participant underwent 8 visits to the study site: In addition
to a screening visit at enrolment and a follow-up visit at the end
of the trial, each period consisted of a bronchoscopy eligibility visit
and 2 bronchoscopy visits. Study periods were separated by 5 ± 1
weeks (Fig. 1).
At screening, informed consent was obtained and inclusion/
exclusion criteria (medical history, concomitant medication,
electrocardiogram, spirometry, safety labs) were checked. For bron-
choscopy eligibility, a coagulation proﬁle and C-reactive protein (CRP)
check was performed per period. Subjects underwent a baseline
bronchoscopy with BAL and segmental instillation of LPS and saline.
Six hours (cohort 1) or 24 h (cohort 2) after the baseline (ﬁrst) bron-
choscopy, a second bronchoscopy with BAL of segments given LPS
and salinewas performed. Blood samples for biomarker analysis were
collected 30 min prior to as well as 1, 3, 5.5, 8, 10, 23.5, and 26 h
post LPS challenge. All subjects were contacted within 48 h after
discharge from the second bronchoscopy to ensure subjects’ safety.
Study subjects attended the unit for a follow-up visit 7–14 days after
study period 2.
The study was conducted in accordance with Good Clinical Prac-
tice and the Declaration of Helsinki. Subjects gave their written
informed consent. The study was approved by the Ethical Commit-
tee of Hannover Medical School.
2.2. Subjects
A total of 37 subjects were screened of which 25 healthy,
non-smoking subjects (>5 years non-smoking, <1 pack year) were
enrolled in the study (cohort 1: n = 14, cohort 2: n = 11).
Volunteers of both genders were aged 18–50 years and had forced
expiratory volumes in 1 s (FEV1) and forced vital capacity (FVC) ≥ 90%
of predicted normal with FEV1/FVC ≥ 0.7. Twenty subjects (Table 1,
n = 10 per cohort) completed all assessments and were included
into the analysis of inﬂammatory biomarkers. Five subjects
(4 subjects in cohort 1 and 1 subject in cohort 2) discontinued
because of adverse events (AEs) that were not related to study
procedures.
2.3. Bronchoscopy and challenge procedure
Bronchoscopies were performed under pre-medication with
200 μg inhaled salbutamol, mild sedation with intravenous
midazolam (0.05–0.1 mg/kg) and topical anaesthesia with lido-
caine (4% spray, 2% solution, and 2% gel with total lidocaine dose
not exceeding 8.3 mg/kg) [9,21]. Subjects also received oxygen
during the bronchoscopy and recovery phase. At ﬁrst bronchos-
copy, a baseline BAL of a segment in the left lower lobe was
performed with 100 mL of pre-warmed saline. Furthermore, LPS
(40 EU Clinical Center Reference Endotoxin (CCRE), National
Institutes of Health Clinical Center, Bethesda, MD) per kg body
weight in 10 mL sterile saline, equivalent to 4 ng/kg) was
instilled into the right middle lobe and 10 mL sterile saline
(0.9%) were given into one lingula segment of the contralateral
side as control challenge. All subjects were treated with the same
batch of LPS. At the second bronchoscopy under identical
medication both instilled segments were lavaged with 100 mL
saline each.
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2.4. Analysis of inﬂammatory biomarkers
Cytospin slides were prepared on BAL cells using a standard he-
mocytometer. Differential cell counts were performed from cytospin
slides by counting 300 cells per slide. The number and proportion
of monocytes was also evaluated by ﬂow cytometry, using the cell
surface markers CD3-FITC (Becton Dickinson (BD), Heidelberg,
Germany), CD4-PE (BD), CD8-PE (BD), CD14-APC (Beckman Coulter
(BC), Krefeld Germany), CD16-PECy7 (BD) and respective isotype
controls (BD). For each analysis, 5 × 105 cells were mixed with an
equal volume of goat serum (1:25 diluted) and incubated for 20 min
(4 °C). After washing the cells with PBS, pre-determined amounts
of antibodies were added and the cells were incubated in the dark
for 30 min at 4 °C. For biotin-labelled antibodies an additional in-
cubation step with streptavidin-coupled detection antibodies was
performed (30 min, 4 °C) prior to ﬁxation (Fixation reagent (BC),
1:40 diluted, 10 min). Samples were centrifuged, the superna-
tants were discarded and the cells were resuspended in 600 μL PBS
for ﬂow cytometric analysis using an EPICS XL ﬂow cytometer (BC).
The data of 104 gated cells were recorded and analysed using EXPO
32 and EXPO 32 MultiComp software (BC).
Tumour necrosis factor (TNF)-alpha (TNFA), TNF-receptor 1
(TNFR1), TNF-receptor 2 (TNFR2), Interleukin (IL) 1 beta (IL1B),
IL6, IL8, IL10, granulocyte-colony stimulating factor (CSF3),
chemokine (C–X–C motif) ligand 1 (CXCL1), chemokine (C–C motif)
ligand 4 (CCL4), and chemokine (C–C motif) ligand 2 (CCL2) were
analysed in multiplexed panels by electrochemiluminescence on
SECTOR Imager 6000 (Meso Scale Discovery, Rockville, USA). ELISAs
were used to analyse chemokine (C–X–C motif) ligand 5 (CXCL5),
L-selectin (SELL), and IL-1RN (all R&D), lactoferrin (LTF, Calbiochem),
myeloperoxidase (MPO, Immundiagnostic), albumin (ALB, Bethyl
Labs Inc), Clara cell protein (CC16, SCGB1A1, Biovendor) and
surfactant protein-D (SPD, SFTPD, Biovendor). Plasma C-reactive
protein (CRP) was measured by immunoturbidimetry and plasma
procalcitonin (CALCA) was analysed using immune ﬂuorescence.
All assays were performed according to the instructions provided
by the respective manufacturers. Abbreviations of proteins are
given according to http://www.genenames.org/and aliases can be
derived from eg “Pubmed Gene” search http://www.ncbi.nlm.nih
.gov/gene.
2.5. Safety analysis
AEs were monitored from the date of informed consent to 28
days after the subject’s last visit. A 12-lead electrocardiogram was
performed at screening. Safety clinical laboratory tests, urinalysis,
and physical examinationwere performed at screening and at follow-
up. Vital signs (blood pressure and pulse) were assessed at screening,
on bronchoscopy days, and at follow-up. Oxygen saturation and body
temperature were measured repetitively on bronchoscopy days. Spi-
rometry was conducted at screening as well as prior to and 4 h after
each bronchoscopy.
2.6. Statistics
To quantify intra- and inter-subject variability, an analysis of co-
variance was conducted for each inﬂammatory marker, separately
for each cohort. The model included terms for period, BAL saline
control (1 variable for the average of 2 periods saline values, and
1 variable for the difference from average of each periods saline
value) and subject as a random effect. The type 3 tests of ﬁxed effects,
covariance parameter estimates (with standard errors) and period
comparison with 95% conﬁdence intervals (CIs) are presented.
Highly skewed endpoints such as cell counts and supernatant
cytokines were natural log transformed. Saline values were also
natural log transformed before averaging to derive covariates. To
check model adequacy, plots of model residual values on a normal
scale against residual rank were visually inspected for linearity, and
plots of residual values against dependent variable values enabled
visual checks of residual variance homogeneity.
To quantify the proﬁle of BAL inﬂammatorymarkers (i.e. the effect
of LPS on BAL markers) at 6 h and 24 h post LPS, a separate anal-
ysis of covariance was conducted for each BAL inﬂammatorymarker.
The model included terms for cohort, period, BAL saline control (see
above) and subject as a random effect. The type 3 tests of ﬁxed
effects, covariance parameter estimates (with standard errors) and
period comparison with 95% CIs are presented.
We assessed the within subject (WS) and between subject (BS)
variation and computed the intra-class correlation coeﬃcient
[ICC = 100*(BS/(BS + WS))]. For WS > BS (ICC < 50%) there would
be no advantage for cross-over designs in future studies.
Fig. 1. Study design.
Table 1
Mean (SD) subject demographics.
Cohort 1 (n = 10) Cohort 2 (n = 10)
Age (years) 33.2 (8.4) 30.3 (7.4)
Gender (n) male/female 9/1 6/4
Weight (kg) 81.8 (6.4) 76.5 (12.9)
Height (cm) 182.0 (7.9) 177.3 (6.4)
SD: standard deviation.
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Samples that were below the lower limit of quantiﬁcation were
assigned a value at the midpoint between 0 and the lower limit of
quantiﬁcation. Values of 0 (×104 or 106) were set to 0.001 (×104 or
106) prior to natural log transformation for analysis purposes.
3. Results
Segmental endotoxin challenge with 40 EU CCRE/kg in healthy
volunteers induced a signiﬁcant inﬂammatory response in BAL com-
pared to vehicle instillation both at 6 h and 24 h after instillation.
The procedure was safe and well tolerated. While the pulmonary
response to LPS was strictly localized, mild systemic inﬂamma-
tion was observed which was caused both by LPS as well as the
bronchoscopic procedure.
BAL ﬂuid recovery was slightly lower in the baseline segment
compared to segments instilled with either saline or endotoxin.
Therefore, all BAL variables were reported and standardized per mL
recovered BAL ﬂuid. In cohort 2, for example, median BAL recov-
ery from the saline segment (period 1: 77 mL, period 2: 76 mL) and
LPS treated segments (76, 77 mL) was signiﬁcantly different com-
pared to the baseline segment (68, 70mL, repeatedmeasures ANOVA
p < 0.02). Recovery of BAL ﬂuid was not different between periods.
3.1. Cellular response
Mean BAL cell viability (%) for both cohorts at each assessment
ranged from 87% to 93%, with mean epithelial cells being less than
1% of total cells at all assessments. These data suggest that instil-
lation of LPS and saline did not alter airway mucosal integrity.
Following LPS challenge, an inﬂux of inﬂammatory cells was ob-
served in both cohorts. Invading cells were mainly neutrophils and
monocytes (Table 2, Fig. 2). The cellular increase was more pro-
nounced in cohort 2 at 24 h compared to 6 h post challenge. Due
to the inﬂux of monocytes and neutrophils the mean percentage
of macrophages decreased correspondingly. Absolute numbers of
lymphocytes in BAL following LPS challenge were signiﬁcantly in-
creased at 24 h but not 6 h compared to baseline conditions while
saline had little effect. The fold-increase in lymphocytes was far less
compared with neutrophils and monocytes.
3.2. Cytokine-chemokine response
Concentrations of cytokines, chemokines, and protein biomarkers
in BAL ﬂuid are listed in Table 3. For a number of markers, BAL con-
centrations at baseline and following saline challenge were below
the limit of detection of the respective assays.
All measured markers except CC16 and SPD showed increased
concentrations after LPS challenge at least at one time point (6 h
or 24 h). Acute-phase inﬂammatory mediators such as IL6, IL8, IL1B,
and TNFA, were already increased 6 h after LPS challenge and showed
lower levels at 24 h. ALB, LTF, and SELL on the other hand, showed
higher values at 24 h compared to 6 h. IL10 was only consistently
above the limit of quantiﬁcation at 6 h post LPS challenge. Any direct
comparison between 6 and 24 h, however, has to be interpreted with
care, as these values were derived from different cohorts.
3.3. Inter- and intrasubject variability of the inﬂammatory response
A summary of the variability for a selection of cellular and soluble
BAL biomarkers is presented in Table 4. The within-subject vari-
ability was higher than the between-subject variability for most of
the markers as indicated by an ICC < 50%. For neutrophils, eosino-
phils and monocytes, variability of cell numbers and percentages
was predominantly higher at 6 h compared with 24 h leading to
higher samples sizes when aiming to demonstrate a 50% reduc-
tion of the LPS-induced cell inﬂux. In contrast, for cytokine/
chemokines such as CSF3 or CCL4 variability was higher at 24 h
compared to 6 h leading to higher samples sizes, respectively.
Table 2
Cellular composition of BAL ﬂuid. Data is presented separately for the 2 repeated challenges (periods) within 5 ± 1 weeks. Cohort 1: BAL 6 h after challenge, cohort 2: BAL
24 h after challenge. Data is presented as median (IQR). Repeated measures ANOVA including challenges and periods.*p < 0.05, ***p < 0.001 comparison between “Saline”
and “LPS” segments derived from post hoc analysis (Newman-Keuls-Test). The analysis was performed on untransformed data for cell percentages and on log transformed
data for cell counts. #p < 0.05, ###p < 0.001 for the comparison between cohorts for the LPS challenged segment. For this analysis the mean level of both periods was
calculated and the comparison was performed by Mann–Whitney test for untransformed cell percentages and by t-test for log transformed cell counts.
Challenge Baseline LPS Saline
Period 1 2 1 2 1 2
Cohort 1
Macrophages % 91.9 (3.2) 92.1 (3.1) 35.8 (40.5)*** 28.0 (20.2)***# 88.3 (5.6) 88.6 (2.7)
Monocytes 2.1 (0.9) 2.2 (1.8) 5.9 (2.2)* 7.3 (3.2)*# 3.2 (1.3) 3.8 (1.6)
Neutrophils 1.2 (1.2) 0.7 (0.5) 53.5 (39.9)*** 58.9 (30.7)*** 3.0 (1.3) 1.7 (1.3)
Lymphocytes 3.5 (3.3) 3.0 (2.3) 3.5 (4.5) 2.9 (2.3) 4.0 (2.1) 4.9 (3.1)
Eosinophils 0.0 (0.0) 0.1 (0.2) 0.2 (0.48) 0.2 (0.8) 0.0 (0.2) 0.1 (0.7)
Macrophages 104/mL 11.1 (3.7) 11.5 (6.5) 6.5 (2.9) 9.0 (3.3)### 10.0 (3.7) 13.3 (6.1)
Monocytes 104/mL 0.2 (0.1) 0.2 (0.2) 1.1 (1.5)*** 2.5 (1.2)***### 0.3 (0.1) 0.5 (0.3)
Neutrophils 104/mL 0.14 (0.16) 0.09 (0.08) 10.2 (17.1)*** 19.3 (15.9)***### 0.35 (0.14) 0.31 (0.30)
Lymphocytes 104/mL 0.37 (0.27) 0.39 (0.59) 0.63 (0.56) 1.04 (0.10)### 0.44 (0.32) 0.62 (0.35)
Eosinophils 104/mL 0.00 (0.00) 0.01 (0.03) 0.05 (0.10) 0.09 (0.23) 0.00 (0.01) 0.01 (0.06)
Total cell count 104/mL 11.8 (4.3) 12.3 (6.9) 19.1 (16.0)* 29.6 (14.0)*### 11.1 (4.0) 15.9 (6.2)
Cohort 2
Macrophages % 92.1 (8.0) 89.8 (4.1) 14.0 (5.2)*** 16.8 (7.1)*** 85.4 (9.9) 88.0 (6.1)
Monocytes 1.6 (1.0) 1.7 (0.6) 12.8 (7.0)*** 13.9 (9.9)*** 2.1 (3.2) 2.3 (1.1)
Neutrophils 0.9 (0.7) 0.9 (1.1) 67.4 (14.6)*** 64.0 (8.7)*** 1.7 (1.5) 2.5 (1.5)
Lymphocytes 5.2 (7.9) 6.7 (4.2) 3.7 (3.1)* 3.1 (2.6)* 5.7 (4.3) 7.0 (6.7)
Eosinophils 0.1 (0.3) 0.2 (0.2) 0.1 (0.2) 0.2 (0.5) 0.2 (0.2) 0.0 (0.2)
Macrophages 104/mL 7.2 (5.4) 7.1 (3.4) 12.0 (8.4)* 17.3 (9.8)* 10.7 (7.0) 10.4 (3.0)
Monocytes 104/mL 0.2 (0.1) 0.2 (0.1) 10.9 (6.4)*** 24.5 (23.8)*** 0.3 (0.4) 0.3 (0.2)
Neutrophils 104/mL 0.07 (0.07) 0.07 (0.14) 70.6 (29.7)*** 77.3 (44.6)*** 0.13 (0.34) 0.29 (0.38)
Lymphocytes 104/mL 0.47 (0.80) 0.54 (0.39) 3.58 (3.59)*** 3.36 (5.72)*** 0.48 (0.85) 0.91 (1.24)
Eosinophils 104/mL 0.00 (0.02) 0.01 (0.02) 0.05 (0.19) 0.09 (0.43) 0.02 (0.02) 0.00 (0.07)
Total cell count 104/mL 8.2 (6.6) 7.8 (3.6) 100.1 (40.0)*** 132.9 (70.2)*** 12.1 (8.8) 12.2 (2.4)
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Fig. 2. Change in BAL neutrophils and monocytes 6 h (cohort 1) and 24 h (cohort 2) after segmental LPS challenge. The ﬁlled and the open symbols differentiate between
the ﬁrst and the second challenge performed within a period of 5 ± 1 weeks. Baseline refers to the control segment, which was lavaged prior to the segmental challenge.
Saline refers to the control segment that was challenged with saline only. Medians (interquartile range, IQR). For statistical comparisons please refer to Table 2.
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3.4. Systemic response
Baseline values (before the ﬁrst bronchoscopy) of plasmamarkers
are listed in Table 5. The fold-changes for IL6, CRP, CALCA and
CC16 compared to baseline are shown in Fig. 3. IL6 and CC16 as
well as LTF, CCL2, and CCL4 (data not shown) clearly increased
after LPS challenge in both cohorts. The increase in MPO was
small and only signiﬁcant, if both cohorts and periods were analysed
together.
The bronchoscopy procedure had a small effect on CC16, as shown
by a delayed decline in cohort 1 (8 and 10 h) and a slight increase
at 26 h in cohort 2. CALCA seemed to respond selectively to the BAL
procedure post LPS challenge, showing a pronounced increase after
the second bronchoscopy in cohort 1. CRP was signiﬁcantly in-
creased the day following LPS challenge with higher values in cohort
1 compared to cohort 2 potentially also indicating an effect of the
BAL procedure. No systemic effects of LPS were seen for SELL and
SPD. While there was a signiﬁcant increase in CCL2 in both periods
up to the 5.5 h time point in cohort 1, this was not detectable in
cohort 2, which is diﬃcult to interpret. A similar difference between
cohorts was also seen for CCL4 and TNFA.
3.5. Reproducibility of systemic response
As shown in Fig. 3, the time course of selected markers was
similar between periods. CC16, LTF, SELL, CCL2, CCL4, MPO, SPD and
TNFA showed signiﬁcant correlations when plasma concentra-
tions of all 8 time points (0–26 h) were compared between periods
(subjects of both cohorts included). For CRP and CALCA this was also
observed, but only for the later time points (>10 h).
3.6. Relationship between systemic and local markers of
inﬂammation
We analyzed the relationship between systemic markers and the
level of neutrophils in BAL following LPS challenge. In cohort 1, we
observed no or only very weak correlations between plasma me-
diator levels at the different time points and the percentage or the
Table 3
Inﬂammation biomarkers in BAL ﬂuid. For details refer to Table 2. Comparisons for markers with concentrations below the limit of detection (bld) for “Saline” or “LPS” were
not performed (eg IL10, IL1B). For abbreviations refer to Method section.
Challenge Baseline LPS Saline
Period 1 2 1 2 1 2
Cohort 1
Total Protein μg/mL 74 (38) 74 (30) 102 (66) 100 (20)## 84 (20) 80 (29)
ALB μg/mL 14.4 (9.9) 11.6 (9.2) 20.3 (18.1) 24.7 (10.1)# 18.0 (12.6) 18.6 (5.1)
CC16 pg/mL 639 (891) 816 (400) 708 (658) 951 (773) 1240 (623) 1165 (461)
GCSF pg/mL 13 (7) 10 (7) 516 (250)*** 330 (243)***## 16 (13) 25 (24)
CXCL5 pg/mL bld bld 332 (232)*** 571 (155)***### 32 (54) 44 (41)
CXCL1 pg/mL 457 (159) 333 (204) 926 (411)*** 1230 (528)***## 389 (184) 348 (138)
IL10 pg/mL bld bld 3 (1) 4 (1)### bld bld
IL1B pg/mL bld bld 40 (26) 43 (34)### bld bld
IL1RN pg/mL bld bld 1345 (724) 1425 (1217)### bld bld
IL6 pg/mL bld bld 2135 (1040) 2165 (940)### bld bld
IL8 pg/mL 9 (4) 7 (4) 1091 (1468)*** 2090 (378)***### 14 (25) 24 (57)
LTF μg/mL 84.9 (42.0) 107.8 (134.0) 168.5 (112.5) 169.5 (60.0) 106.4 (70.9) 96.5 (86.9)
SELL ng/mL 137 (193) 294 (251) 964 (1205)*** 1135 (580)***# 310 (279) 286 (187)
CCL2 pg/mL bld bld 469 (274)*** 484 (172)***### 35 (20) 45 (30)
CCL4 pg/mL bld bld 5495 (3925)*** 7525 (2780)***### 4 (42) 26 (109)
MPO ng/mL 5 (1) 5 (5) 18 (9) 25 (18)* 6 (7) 6 (7)
SPD ng/mL 480 (162) 481 (308) 365 (338) 413 (281)# 459 (254) 470 (244)
TNFR1 pg/mL 99 (83) 122 (37) 244 (82)** 245 (80)* 111 (52) 138 (60)
TNFR2 pg/mL 32 (29) 35 (10) 135 (51)*** 153 (100)***### 31 (11) 38 (12)
TNFA pg/mL bld bld 65 (84) 71 (49)### bld bld
Cohort 2
Total Protein μg/mL 82 (51) 93 (50) 211 (72)*** 248 (165)*** 108 (73) 80 (89)
ALB μg/mL 9.3 (4.4) 13.9 (10.3) 41.0 (23.1)** 50.8 (41.9)*** 15.1 (18.9) 13.5 (18.4)
GCC16 pg/mL 1120 (615) 1245 (691) 1265 (679) 964 (511) 1415 (525) 1205 (645)
GCSF pg/mL 8 (8) 8 (18) 115 (251)** 90 (143)*** 22 (29) 15 (18)
CXCL5 pg/mL bld bld 86 (46) 94 (46) bld bld
CXCL1 pg/mL 445 (136) 492 (398) 389 (141) 408 (135) 428 (227) 404 (294)
IL10 pg/mL bld bld bld bld bld bld
IL1B pg/mL bld bld bld bld bld bld
IL1RN pg/mL bld bld 147 (145) 156 (125) bld bld
IL6 pg/mL bld bld 62 (103) 55 (35) bld bld
IL8 pg/mL 10 (7) 9 (5) 45 (48)* 47 (19)*** 21 (11) 12 (6)
LTF μg/mL 69.0 (61.0) 105.5 (53.3) 180.0 (118.8) 213.0 (59.0)* 70.5 (57.9) 74.9 (49.9)
SELL ng/mL 216 (203) 370 (394) 2630 (1028)*** 2635 (2205)*** 430 (205) 356 (383)
CCL2 pg/mL bld bld 45 (10) bld bld bld
CCL4 pg/mL bld bld 31 (50) 28 (28) bld bld
MPO ng/mL 5 (2) 5 (4) 64 (48)* 34 (40)** 7 (4) 6 (8)
SPD ng/mL 437 (275) 434 (391) 664 (615) 533 (664) 514 (486) 449 (346)
TNFR1 pg/mL 100 (66) 74 (96) 303 (231)** 408 (266)*** 139 (131) 124 (142)
TNFR2 pg/mL 22 (11) 20 (27) 368 (148)*** 438 (284)*** 39 (38) 36 (38)
TNFA pg/mL bld bld 4 (4) 3 (3) bld bld
Repeated measures ANOVA including challenges and periods.*p 0.05,**p 0.001 comparison between “Saline” and “LPS” segments derived from post hoc analysis (Newman-
Keuls-Test). The analysis was performed on log transformed data. #p 0.05, ##p 0.001 for the comparison between cohorts for the LPS challenged segment. For this analysis
the mean level of both periods was calculated and the comparison was performed by t-test for log transformed data.
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number of neutrophils in BAL ﬂuid 6 h after segmental LPS chal-
lenge. In cohort 2, the plasma levels of MPO showed a positive
correlation, while the plasma levels of TNFA showed a negative cor-
relation with the percentage of neutrophils in BAL ﬂuid 24 h after
the LPS challenge. For MPO these correlations ranged between
r = 0.50 and r = 0.67, while these were lower for TNFA and not sig-
niﬁcant at all time points (r = −0.45 to r = −0.54).
3.7. Safety
In general, study procedures were safe and well tolerated. Four
subjects in cohort 1 and 1 subject in cohort 2 were discontinued
or withdrawn from the study because of adverse events. These in-
cluded moderate diarrhoea (day 1 to day 2), mild cough (day 26 to
day 29), and mild to moderate lymphocytic alveolitis as an inci-
dental ﬁnding in the baseline BAL (in 2 subjects in period 1 of cohort
1 and 1 subject in period 2 of cohort 2).
The most frequently reported treatment (LPS challenge) emer-
gent adverse events (TEAEs) were pyrexia (5 subjects) and headache
(4 subjects) in cohort 1 and headache (3 subjects) in cohort 2. No
subject reported pyrexia in cohort 2. Nausea and alveolitis were
each reported for 2 subjects in cohort 1 and 1 subject in cohort 2.
No other TEAE was reported for more than 2 subjects overall. All
TEAEs were mild or moderate in intensity, with the exception of
pleuritic pain in one subject in cohort 1 which was rated of severe
intensity.
4. Discussion
Instillation of endotoxin into the lung resulted in the expected
localized inﬂammatory response that was mainly characterized by
an inﬂux of neutrophils and monocytes. The cellular response was
detectable at 6 h but was clearly more pronounced at 24 h after seg-
mental LPS challenge. In contrast, BAL cytokine levels showed amore
pronounced increase at 6 h compared to 24 h post LPS. This ‘two-
phase’ response is in line with previously reported data [6]. In
addition, pulmonary instillation of LPS induced a systemic re-
sponse with characteristic proﬁles for various inﬂammatorymarkers
in plasma.
Segmental LPS instillation by bronchoscopy has ﬁrst been de-
scribed by O’Grady and co-workers [6]. We have recently shown
that this technique can be applied as a model to test novel
Table 4
Within- and between subject variability for selected BAL inﬂammatory cells and supernatant biomarkers. The sample size required to detect a 50% reduction of the respec-
tive cell or cytokine is presented in the last 2 columns of the table. For a detailed methodology refer to the Material and method section.
Marker Cohort Post LPS response
(adjusted mean)
Between subject
variance
component*
Within subject
variance
component*
Total variance* ICC (%) Sample size required to
detect 50% reduction
Crossover Parallel†
Neutrophils (%) 1 52.565 316.64 193.42 510.06 62.08 5 12
2 65.100 8.71 60.64 69.35 12.57 1 2
Neutrophils (104/mL) 1 11.225# 1.02 1.05 2.07 49.13 35 68
2 64.174# 0.00 0.37 0.37 0.00 12 12
Macrophages (%) 1 35.525 203.43 278.85 482.28 42.18 14 24
2 17.435 0.00 74.25 74.25 0.00 16 16
Macrophages (106/mL) 1 0.069# 0.00 0.13 0.13 0.00 5 5
2 0.158# 0.21 0.10 0.31 67.33 4 11
Monocytes (%) 1 7.280 2.28 11.91 14.20 16.08 15 17
2 13.175 25.20 32.65 57.85 43.56 12 21
Monocytes (106/mL) 1 0.015# 0.19 1.17 1.37 14.09 39 45
2 0.109# 0.26 0.82 1.08 23.84 27 36
TNFA (pg/mL) 1 53.775 0.31 0.57 0.88 35.54 19 29
2 2.655 0.16 0.35 0.51 31.85 12 17
IL8 (pg/mL) 1 1199.211 0.32 0.25 0.57 55.71 9 19
2 42.394 0.05 0.32 0.37 12.85 11 12
CSF3 (pg/mL) 1 392.872 0.00 0.52 0.52 0.59 17 18
2 97.293 0.29 1.19 1.48 19.81 39 49
CCL4 (pg/mL) 1 5817.386 0.27 0.41 0.69 39.87 14 23
2 20.882 0.00 0.90 0.90 0.00 30 30
BAL: bronchoalveolar lavage; ICC: intra-class correlation; LPS: lipopolysaccharide; for abbreviations of biomarkers refer to Method section. Note: Post LPS re-
sponse = average least squares mean over the 2 periods, from a model with ﬁxed terms for period, average saline and difference from average saline, random subject term.
# Adjusted geometric means are back-transformed least squares means for markers analysed on a log scale. * Log transformed data for markers analysed on a log scale.
ICC = 100 × Between-Subject/Total Variability. High values of ICC suggest advantage to cross-over designs. † Numbers are per arm.
Table 5
Plasma levels of inﬂammation biomarkers at baseline. Data prior to segmental LPS challenge. For abbreviations refer to Method section.
Cohort 1 2
Period 1 2 1 2
CC16 ng/mL 40.0 (17.5) 42.3 (18.9) 35.7 (8.4) 34.3 (7.4)
CRP mg/L 0.3 (0.0) 0.3 (0.3) 1.0 (0.7) 1.3 (0.4)
IL6 ng/mL 1.2 (1.7) 2.5 (2.1) 3.3 (2.8) 2.0 (1.9)
LTF ng/mL 199.0 (151.0) 184.5 (84.8) 183.0 (44.3) 181.0 (44.5)
SELL ng/mL 804.5 (182.0) 758.0 (280.3) 862.0 (196.3) 859.5 (87.3)
CCL2 ng/mL 176.0 (75.8) 153.0 (60.3) 194.0 (48.8) 191.5 (59.0)
CCL4 ng/mL 89.0 (15.3) 86.4 (20.9) 52.9 (30.0) 64.8 (20.2)
MPO ng/mL 26.6 (8.2) 26.2 (11.9) 31.6 (19.2) 36.7 (13.9)
CALCA ng/mL 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0)
SPD ng/mL 55.7 (31.7) 63.1 (22.9) 97.7 (35.9) 97.0 (48.3)
TNFA ng/mL 4.6 (2.4) 3.1 (1.7) 3.0 (2.2) 3.4 (2.2)
56 O. Holz et al./Pulmonary Pharmacology & Therapeutics 35 (2015) 50–59
Fig. 3. Change in plasma concentrations (fold increase compared to baseline prior to LPS (values see in Table 5). Medians (interquartile range, IQR). Closed symbols: period
1, open symbols: period 2.
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anti-inﬂammatory agents [9]. Instillation of 4 ng LPS/kg bodyweight,
which has been used in previous studies, results in a marked in-
crease in the number and percentage of neutrophils and monocytes
in the respective lung segment. It is important to note that the in-
ﬂammatory response is restricted to the challenged segment.
Compared to baseline, there is generally only a marginal increase
in neutrophils and monocytes in the saline-challenged segment of
the contralateral side of the lung.
The spectrum and the range of the cellular response reported
here is similar to those described by O’Grady [6] and our own group
[9]. Compared to the study by O’Grady and coworkers we ob-
served a smaller neutrophil inﬂux in our 6 h cohort while total cell
numbers were higher in our 24 h cohort. The pulmonary cytokine
proﬁle was very similar between studies [6]. While the proﬁles of
the systemic response of both studies are diﬃcult to compare, both
studies found maximum concentrations of CRP at about 24 h and
the IL6 peak in plasma at about 6 h.
Segmental LPS challenge in our study was well tolerated. This
is in accordance with published studies which so far have not re-
ported evidence of serious adverse effects or persistent sequelae.
For segmental challenges with up to 4 ng LPS/kg body weight only
mild reductions in blood pressure (max. ∼ 10 mmHg systolic and
diastolic) and oxygen saturation (≤3%) as well as small increases in
body temperature (typically ≤ 1 °C) and changes in heart rate
(max. ± 20 bpm) have been reported [5,9] as evidence for mild sys-
temic effects.
All subjects showed a cellular response to LPS which was larger
and more homogeneous at 24 h compared to 6 h following chal-
lenge. Increases of cell fractions ranged from 5 to 80 fold at 6 h and
from 50 to 80 fold at 24 h. Both, time course and magnitude was
shown to be repeatable. For cellular and supernatant inﬂammato-
ry markers in BAL we calculated the intra- and inter-individual
variability as well as the intraclass correlation coeﬃcient (ICC) as
the ratio of the between-subject to total variability, i.e. the sum of
within-subject and between-subject variability in percent. Conse-
quently, a ratio of <50% indicates that within-subject variance
outweighs between-subject variance suggesting there is no advan-
tage for cross-over designs in future studies. The ICC was below 50%
for the majority of markers.
The data on variance were also used to calculate sample sizes
for various markers. Numerically, the percentage of BAL neutro-
phils was the outcome variable where eﬃcacy of anti-inﬂammatory
interventions can be demonstrated with very few subjects (Table 4).
On average, 12–20 subjects will be needed to demonstrate a 50%
reduction of a given variable. Lower effect sizes with assumed re-
ductions of a given outcome variable of e.g. 25% will increase sample
size numbers accordingly. Sample sizes for a cross-over design were
mostly found lower or equal to the respective sample size per group
in a parallel design suggesting that recruitment could be simpli-
ﬁed provided that a period/sequence effect can be excluded for the
investigational drug. Overall, these data are very useful for the plan-
ning and prioritizing primary and secondary endpoints in proof-
of-principle clinical trials.
The observed inﬂux of neutrophils in the segmental LPS chal-
lenge model by far exceeds the effects described after ozone
exposure. The percentage of neutrophils in BAL ﬂuid at different time
points after ozone exposure seldom exceeds 10% [22]. Inhaled ozone
as well as inhaled LPS are likely to act in the more central parts of
the lung. Therefore, induced sputum has been used to analyse the
anti-inﬂammatory response to ozone and LPS inhalation chal-
lenges [3,20,23]. The mean baseline sputum neutrophil percentage
has been described to range between 27% and 38% [24–26] but values
above 50% can be observed. Therefore, the maximum increase of
sputum neutrophil percentage is generally limited to 2–5 fold. In
addition, subjects that do not show a suﬃcient inﬂammatory
response to ozone have been reported, which also makes a
pre-screening of subjects advisable. In this regard, the robust and
much larger inﬂammatory response to segmental LPS has a clear
advantage.
In this study systemic increases were observed for a number of
markers over a 5–10 h period post LPS challenge, including IL6, CCL2,
LTF, CC16 and CCL4 with levels returning to baseline by 26 h. The
responses were reproducible, showing basically the same kinetics
and peak levels in the repeated challenges. The systemic response
was also comparable to the one reported previously by the group
of O’Grady [6]. The majority of systemic markers responded to the
LPS challenge, but not to the bronchoscopic procedure itself. An ex-
ception was CALCA, which showed a repeatable increase starting
8 h after the challenge, but only in subjects of cohort 1, which un-
derwent a bronchoscopy at 6 h. Accordingly, there were also higher
CRP values in cohort 1 at 23 h. Differences in the overall level of
CCL4, MPO, SELL, and especially SPD between cohorts are likely to
be related to differences between the individuals assigned to the
2 cohorts. Due to a lack of a group of unchallenged subjects we
cannot estimate to what extent the systemic responses might have
been affected by circadian variation.
No signiﬁcant relationship between systemic markers of inﬂam-
mation and BAL neutrophil numbers as the dominant cell type after
segmental LPS challenge were found. Although subjects with higher
baseline plasmaMPO concentrations tended to have higher BAL neu-
trophil percentages, the association appears to be too weak to be
used as pre-selection criteria for a neutrophil-dominant response
to LPS.
5. Conclusion
Taken together, segmental instillation of endotoxin in healthy
volunteers is a safe procedure which induced a pronounced and lo-
calized inﬂammatory response. Here we provide comprehensive data
for the intra- and inter-individual variability of the inﬂammatory
response to instilled LPS to serve in the design of future clinical trials.
The data of this study will also help to choose the appropriate time
point for individual markers. Finally, we were able to show a re-
peatable systemic response with a speciﬁc kinetic for individual
markers, which could help to monitor the inﬂammatory response
after segmental LPS challenge in a less invasive way.
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